Document Detail

Ivabradine Improves Quality of Life in Subjects with Chronic Heart Failure Compared to Treatment with β-Blockers: Results of a Multicentric Observational APULIA Study.
MedLine Citation:
PMID:  24296869     Owner:  NLM     Status:  Publisher    
Objectives: Ivabradine (IVA), a selective If current inhibitor decreasing the heart rate (HR) in patients with sinus rhythm, has been added to the most recent European Guidelines on heart failure. This selective treatment reduces HR exclusively while fully preserving myocardial contractility and relaxation, atrioventricular conduction, and ventricular repolarization, as well as blood pressure. The aim of this study was to evaluate the improvement of quality of life (QOL) in patients with chronic heart failure (CHF) treated with IVA versus two β-blockers (bisoprolol and carvedilol). Methods: We evaluated if a 1-month treatment with IVA (5 mg b.i.d.) or β-blockers (carvedilol 6.25 mg b.i.d. or bisoprolol 1.25 mg b.i.d.) improves the QOL (assessed by SF-36 questionnaire) in patients with CHF with reduced left ventricular ejection fraction (<50%). SF-36 was tested in 221 CHF patients (mean age 64 ± 6 years) randomized into two groups (IVA group - 110 patients; β-blockers group - 111 patients). Data of QOL questionnaire and HR were collected by an interview during a clinical visit both at prescription time (basal) and after 1 month of therapy with IVA or β-blockers. QOL life and HR results after 1-month of therapy (T1) with IVA were compared with basal values (T0). Results: The IVA versus β-blockers treatment was associated with a significant improvement of physical functioning (p < 0.001 vs. p < 0.01), physical role functioning (p < 0.001 vs. p < 0.01), emotional role functioning (p < 0.01 vs. p < 0.85), and mental health scales (p < 0.001 vs. p < 0.01). HR in the IVA group was significantly lower compared to the group of patients treated with β-blockers (63 vs. 67 bpm; p < 0.001). Conclusions: IVA treatment significantly improves the QOL in patients with CHF without any deleterious impact on hemodynamics, and may be beneficial in these patients without other adverse effects associated with β-blockers. © 2013 S. Karger AG, Basel.
G Riccioni; L Masciocco; A Benvenuto; P Saracino; D De Viti; F Massari; G Meliota; F Buta; G Speziale
Related Documents :
24685379 - Five-year real world outcomes of geoform ring implantation in patients with ischemic mi...
24455059 - Comparative split-mouth study of the anesthetic efficacy of 4% articaine versus 0.5% bu...
25034549 - Return to sport following amputation.
9190979 - A randomized study comparing retroperitoneal drainage with no drainage after lymphadene...
23373869 - Remnant uptake as a postoperative oncologic quality indicator.
18794429 - Planned early discharge-elective surgical readmission pathway for patients with gallsto...
10468719 - A comparative analysis of nephrostomy, jj stent and urgent in situ extracorporeal shock...
24991389 - Fixed-dose combination gel of adapalene and benzoyl peroxide plus doxycycline 100 mg ve...
11226799 - Reduction in intraocular pressure after laser in situ keratomileusis.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-11-27
Journal Detail:
Title:  Pharmacology     Volume:  92     ISSN:  1423-0313     ISO Abbreviation:  Pharmacology     Publication Date:  2013 Nov 
Date Detail:
Created Date:  2013-12-3     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0152016     Medline TA:  Pharmacology     Country:  -    
Other Details:
Languages:  ENG     Pagination:  276-280     Citation Subset:  -    
Cardiology Unit, San Camillo del Lellis Hospital, Manfredonia, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Improved photoluminescence and sensing stability of porous silicon nanowires by surface passivation.
Next Document:  Allopurinol as a Preventive Contrivance after Acute Ischemic Stroke in Patients with a High Level of...